D. Western Therapeutics Institute
4576
Needs Well
3992
Daiwa Cycle
5888
Osaka Yuka Industry
4124
Liberta
4935
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 6.55%22.59B | 2.75%86.64B | 4.26%21.31B | 2.26%22.41B | 0.43%21.72B | 4.25%21.2B | 14.01%84.32B | 4.70%20.44B | 15.85%21.92B | 17.81%21.63B |
Cost of revenue | 2.51%11.5B | -2.92%46.78B | -1.11%11.54B | 0.65%12.12B | -6.12%11.9B | -4.91%11.22B | 13.20%48.19B | 2.35%11.67B | 11.32%12.04B | 21.78%12.68B |
Gross profit | 11.07%11.08B | 10.32%39.86B | 11.40%9.77B | 4.23%10.3B | 9.70%9.82B | 16.91%9.98B | 15.10%36.13B | 8.01%8.77B | 21.90%9.88B | 12.60%8.95B |
Operating expense | 9.68%7.09B | 4.02%27.26B | 9.46%7.05B | 5.18%7.07B | -0.45%6.68B | 1.99%6.47B | 9.69%26.2B | 2.14%6.44B | 7.81%6.72B | 13.13%6.71B |
Staff costs | 2.27%2.74B | ---- | ---- | -39.90%851M | 16.71%2.73B | 16.80%2.68B | ---- | ---- | 24.32%1.42B | 0.91%2.34B |
Selling and administrative expenses | 17.41%1.31B | ---- | ---- | -11.80%1.3B | -36.47%1.15B | -30.46%1.11B | ---- | ---- | -8.44%1.48B | 50.33%1.8B |
-Selling and marketing expense | 5.26%340M | ---- | ---- | 26.98%466M | -6.32%326M | -3.00%323M | ---- | ---- | -20.39%367M | 34.88%348M |
-General and administrative expense | 22.38%968M | ---- | ---- | -24.64%835M | -43.68%820M | -37.67%791M | ---- | ---- | -3.65%1.11B | 54.56%1.46B |
Depreciation and amortization | 10.53%315M | ---- | ---- | 8.51%306M | 5.67%298M | 4.40%285M | ---- | ---- | 2.17%282M | 8.46%282M |
-Depreciation | 10.53%315M | ---- | ---- | 8.51%306M | 5.67%298M | 4.40%285M | ---- | ---- | 2.17%282M | 8.46%282M |
Other operating expenses | 14.31%2.72B | ---- | ---- | 29.96%4.61B | 9.70%2.5B | 9.97%2.38B | ---- | ---- | 10.60%3.55B | 6.10%2.28B |
Operating profit | 13.64%3.99B | 26.95%12.6B | 16.75%2.72B | 2.22%3.23B | 40.04%3.14B | 59.97%3.51B | 32.36%9.93B | 28.41%2.33B | 68.84%3.16B | 11.04%2.24B |
Net non-operating interest income (expenses) | 88.89%68M | 302.56%157M | 1,000.00%55M | 113.64%47M | 171.43%19M | 620.00%36M | 254.55%39M | 5M | 29.41%22M | 450.00%7M |
Non-operating interest income | 70.45%75M | 140.00%192M | 350.00%63M | 96.55%57M | 47.37%28M | 144.44%44M | 17.65%80M | 7.69%14M | -3.33%29M | 58.33%19M |
Non-operating interest expense | -12.50%7M | -14.63%35M | -11.11%8M | 42.86%10M | -25.00%9M | -38.46%8M | -28.07%41M | -30.77%9M | -46.15%7M | -14.29%12M |
Net investment income | -21.73%497M | 105.98%861M | 591.75%477M | 55.30%-312M | -83.29%61M | -25.12%635M | -32.14%418M | -119.56%-97M | -489.94%-698M | 815.69%365M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 199M | 866.67%69M | 0 | 0 | 666.67%69M | 0 | -9M | -18M | 0 | 9M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | 85.71%-1M | 57.00%-86M | 69.17%-37M | 18.60%-35M | 12.50%-7M | 75.86%-7M | -506.06%-200M | -531.58%-120M | -975.00%-43M | -166.67%-8M |
Less:Impairment of capital assets | ---- | --26M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
Less:Other special charges | -85.71%1M | 200.00%45M | 77.78%-4M | --35M | -12.50%7M | -72.00%7M | -54.55%15M | -194.74%-18M | --0 | 166.67%8M |
Less:Write off | ---- | -91.89%15M | -89.13%15M | ---- | ---- | --0 | --185M | --138M | --43M | --0 |
Other non-operating income (expenses) | 28.57%18M | -23.02%97M | -104.76%-1M | 40.00%63M | -16.00%21M | -60.00%14M | -19.23%126M | -38.24%21M | -23.73%45M | -13.79%25M |
Income before tax | 13.90%4.77B | 33.00%13.7B | 51.51%3.22B | 20.59%2.99B | 24.92%3.3B | 37.22%4.19B | 24.86%10.3B | -8.81%2.12B | 16.80%2.48B | 32.80%2.64B |
Income tax | 12.78%1.43B | 21.94%3.26B | 106.43%770M | -20.30%589M | -13.37%635M | 52.77%1.27B | 23.61%2.68B | -35.13%373M | 19.19%739M | 51.13%733M |
Net income | 14.39%3.34B | 36.90%10.44B | 39.93%2.45B | 37.84%2.4B | 39.69%2.67B | 31.37%2.92B | 25.29%7.62B | -0.23%1.75B | 15.88%1.74B | 26.83%1.91B |
Net income continuous operations | 14.38%3.34B | 36.88%10.44B | 39.79%2.45B | 37.92%2.4B | 39.61%2.67B | 31.41%2.92B | 25.31%7.63B | -0.17%1.75B | 15.81%1.74B | 26.89%1.91B |
Noncontrolling interests | -200.00%-1M | -80.00%1M | -200.00%-1M | 100.00%2M | -150.00%-1M | 0.00%1M | 200.00%5M | 1M | 200.00%1M | 166.67%2M |
Net income attributable to the company | 14.46%3.34B | 36.96%10.44B | 39.93%2.45B | 37.89%2.4B | 39.81%2.67B | 31.44%2.92B | 25.11%7.62B | -0.23%1.75B | 15.75%1.74B | 26.42%1.91B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 14.46%3.34B | 36.96%10.44B | 39.93%2.45B | 37.89%2.4B | 39.81%2.67B | 31.44%2.92B | 25.11%7.62B | -0.23%1.75B | 15.75%1.74B | 26.42%1.91B |
Gross dividend payment | ||||||||||
Basic earnings per share | 16.37%71.8017 | 38.18%222.56 | 42.45%52.62 | 39.60%51.43 | 40.79%56.81 | 31.44%61.7 | 25.45%161.07 | -0.22%36.94 | 15.78%36.84 | 26.85%40.35 |
Diluted earnings per share | 16.37%71.8017 | 38.18%222.56 | 42.35%52.5825 | 39.66%51.43 | 40.79%56.81 | 31.44%61.7 | 25.45%161.07 | -0.22%36.94 | 15.75%36.8261 | 26.85%40.35 |
Dividend per share | 0 | 29.49%101 | 29.49%101 | 0 | 0 | 0 | 21.88%78 | 21.88%78 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |